Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Bollen

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Journal of Clinical Microbiology|October 1, 1995
Intermethod variation in detection of human papillomavirus DNA in cervical smearsH L Smits, L J Bollen, S P Tjong-A-Hung, et al.
The Journal of Antimicrobial Chemotherapy|February 5, 2021
The dolutegravir/valproic acid drug-drug interaction is primarily based on protein displacementP D J Bollen, H A B Prins, A Colbers, et al.
The Lancet. HIV|August 9, 2020
Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trialPauline D J Bollen, Cecilia L Moore, Hilda A Mujuru, et al.
The Lancet. HIV|February 21, 2022
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trialHylke Waalewijn, Man K Chan, Pauline D J Bollen, et al.
The Lancet. HIV|July 22, 2022
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trialAnna Turkova, Hylke Waalewijn, Man K Chan, et al.
British Journal of Clinical Pharmacology|September 4, 2024
Influence of age and co-medication on dolutegravir glucuronidation in paediatric patientsTom G Jacobs, Hylke Waalewijn, Lily Houlden, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Journal of Clinical Microbiology|October 1, 1995
Intermethod variation in detection of human papillomavirus DNA in cervical smearsH L Smits, L J Bollen, S P Tjong-A-Hung, et al.
The Journal of Antimicrobial Chemotherapy|February 5, 2021
The dolutegravir/valproic acid drug-drug interaction is primarily based on protein displacementP D J Bollen, H A B Prins, A Colbers, et al.
The Lancet. HIV|August 9, 2020
Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trialPauline D J Bollen, Cecilia L Moore, Hilda A Mujuru, et al.
The Lancet. HIV|February 21, 2022
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trialHylke Waalewijn, Man K Chan, Pauline D J Bollen, et al.
The Lancet. HIV|July 22, 2022
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trialAnna Turkova, Hylke Waalewijn, Man K Chan, et al.
British Journal of Clinical Pharmacology|September 4, 2024
Influence of age and co-medication on dolutegravir glucuronidation in paediatric patientsTom G Jacobs, Hylke Waalewijn, Lily Houlden, et al.
Pageof 3